Evaluation of soluble CD44 protein marker to distinguish the premalignant and malignant carcinoma cases in cervical cancer patients.
about
Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choicesClinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.Risk Stratification System for Oral Cancer Screening.Breast cancer stem cell markers CD44 and ALDH1A1 in serum: distribution and prognostic value in patients with primary breast cancer
P2860
Evaluation of soluble CD44 protein marker to distinguish the premalignant and malignant carcinoma cases in cervical cancer patients.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Evaluation of soluble CD44 pro ...... s in cervical cancer patients.
@en
Evaluation of soluble CD44 pro ...... s in cervical cancer patients.
@nl
type
label
Evaluation of soluble CD44 pro ...... s in cervical cancer patients.
@en
Evaluation of soluble CD44 pro ...... s in cervical cancer patients.
@nl
prefLabel
Evaluation of soluble CD44 pro ...... s in cervical cancer patients.
@en
Evaluation of soluble CD44 pro ...... s in cervical cancer patients.
@nl
P2093
P2860
P1433
P1476
Evaluation of soluble CD44 pro ...... s in cervical cancer patients.
@en
P2093
Lokanatha Valluru
Subramanyam Dasari
Wudayagiri Rajendra
P2860
P2888
P356
10.1007/S12032-014-0139-9
P577
2014-07-27T00:00:00Z